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Purpose: To determine whether the methanol extract of Myelophycus caespitosus (MEMC) downregulates 
the expression of pro-inflammatory mediators in lipopolysaccharide (LPS)-stimulated BV2 microglial cells. 
Methods: Reverse transcription-polymerase chain reaction (RT-PCR) together with Western blot analysis was 
used to evaluate the expression of pro-inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 
(PGE2) as well as their regulatory genes such as inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-
2), in LPS-stimulated BV2 microglial cells. The level of NO production was analyzed using Griess reaction. 
The release of PGE2 was determined using sandwich enzyme-linked immunosorbent assay. The DNA-binding 
activity of nuclear factor-κB (NF-κB) was measured by electrophoretic mobility shift assay. 
Results: MEMC inhibited LPS-induced pro-inflammatory mediators, NO and PGE2, as well as their respective 
genes, iNOS and COX-2, at both protein and mRNA levels, without any significant cytotoxicity. Treatment with 
MEMC also substantially reduced the LPS-induced DNA-binding activity of NF-κB and nuclear translocation of 
NF-κB subunits p65 and p50 via the inhibition of IκBα phosphorylation and degradation. MEMC promoted 
dephosphorylation of Akt that subsequently suppressed the DNA-binding activity of NF-κB in LPS-stimulated 
BV2 microglial cells. 
Conclusion: Collectively, these data suggest that MEMC attenuates expression of pro-inflammatory 
mediators such as NO and PGE2 by suppression of their regulatory genes through the inhibition of Akt-
mediated NF-κB activity. 
 








*Corresponding author:  Email: immunkim@jejunu.ac.kr; Tel: +82 64 754 3427; Fax: +82 64 756 3493
Jayasooriya et al 
Trop J Pharm Res, December 2012;11 (6): 918 
INTRODUCTION 
 
Inflammatory response functions in normal 
cells to protect against tissue wounds and 
microbial infections induced by biological, 
chemical or physical stimuli. However, an 
aberrant inflammatory response can lead to 
overexpression of pro-inflammatory 
mediators such as nitric oxide (NO) and 
prostaglandin E2 (PGE2), which can result in 
tissue destruction and organ damage [1,2]. 
Specifically, over-activated microglial cells 
exert self-cytotoxicity by secreting these pro-
inflammatory mediators, and this plays an 
important role in the pathogenesis of central 
nervous system diseases such as 
Parkinson’s and Alzheimer’s diseases [3]. 
Therefore, agents that attenuate pro-
inflammatory mediators in microglial cells 
may represent promising strategies for 
reducing brain injury and neurodegenerative 
disease. According to a recent study, 
inhibition of nuclear factor-κB (NF-κB) results 
in an anti-inflammatory response by 
downregulation of the expression of inducible 
NO synthase (iNOS) and cyclooxygenase-2 
(COX-2) [4]. Targeting specific cell signaling 
pathways in the inflammatory process is 
expected to be a critical aspect in the 
treatment against inflammation-mediated 
diseases [5]. 
 
Marine algae have been extensively studied 
as they are a rich source of novel structural 
compounds that possess biological activity 
against malignant neoplasms, heart disease, 
high blood pressure, cerebrovascular 
disease, senility, diabetes and liver disease 
[5,6]. In recent reports, we also noted that 
many seaweed extracts significantly 
attenuate the expression of lipopoly-
saccharide (LPS)-stimulated pro-
inflammatory mediators in microglial or 
macrophage cells and may therefore have 
the potential for modulating the LPS-induced 
inflammatory response [7−9]. Myelophycus 
caespitosus has been used as a traditional 
medicine in Northeastern Asia for treating 
inflammatory diseases, skin cancer, colon 
cancer, hematologic malignancy and skin 
whitening. Nevertheless, no scientific reports 
have yet investigated the anti-inflammatory 
properties of M. caespitosus. 
 
This study focused on evaluating the effects 
of the methanol extract of M. caespitosus 
(MEMC) on the expression of NO and PGE2 
and their respective regulatory genes iNOS 





Reagents and chemicals 
 
MEMC was purchased from Jeju HI-Tech 
Industry Development Institute (Jeju, 
Republic of Korea). LPS and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide (MTT) were purchased from Sigma 
Chemical Co. (St. Louis, MO, USA). Rabbit 
anti-human antibodies against iNOS, COX-2, 
p65, p50, phospho (p)-IκBα, and IκBα were 
purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Rabbit anti-human 
antibodies against β-actin, c23, (p)-Akt and 
Akt were obtained from Cell Signaling 
(Beverly, MA, USA). Peroxidase-labeled anti-
rabbit antibody was purchased from KOMA 
Biotechnology (Seoul, Republic of Korea) and 
LY294002 was purchased from Calbiochem 
(San Diego, CA, USA). Dulbecco’s modified 
Eagle’s medium (DMEM) and fetal bovine 
serum (FBS) were obtained from WelGENE 
Inc. (Daegu, Republic of Korea). Other 
chemicals used were purchased from Sigma. 
 
Cell culture and viability assay 
 
BV2 microglial cells were cultured at 37 °C in 
5 % CO2 in DMEM supplemented with 5 % 
FBS and antibiotics. In all experiments, cells 
were pre-treated with the indicated 
concentrations of MEMC 1 h before the 
addition of LPS (1 μg/ml) in serum-free 





BV2 microglial cells (1 × 105 cells/ml) were 
plated onto 24-well plates and pretreated with 
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the indicated concentrations of MEMC for 1 h 
prior to stimulation with 1 μg/ml of LPS for 24 
h. The cell supernatants were collected and 
assayed for NO production using Griess 
reagent. Briefly, the samples were mixed with 
equal volume of Griess reagent (1 % 
sulfanilamide in 5 % phosphoric acid and 0.1 
% naphthylethylenediamine dihydrochloride) 
and then incubated at room temperature for 5 
min. The absorbance was measured at 540 
nm on a microplate reader (MULTISKAN EX, 
Thermo Electron Corporation, Marietta, OH, 
USA). Nitrite concentration was determined 
from a sodium nitrite standard curve. 
 
Measurement of PGE2 
 
The expression levels of PGE2 were 
measured by enzyme-linked immunosorbent 
assay (ELISA) kit (R&D Systems, 
Minneapolis, MN, USA) according to the 
manufacturer’s instructions. Briefly, BV2 
microglial cells (2 × 105 cells/ml) were plated 
in 24-well plates and pretreated with the 
indicated concentrations of MEMC for 1 h 
prior to stimulation with 1 μg/ml of LPS for 24 
h. One hundred microliters of culture media 
were collected for the determination of PGE2 
concentrations by ELISA. 
 
Reverse transcriptase polymerase chain 
reactions (RT-PCR) 
 
Total RNA was extracted from BV2 microglial 
cells using Easy-blue reagent (iNtRON 
Biotechnology, Sungnam, Republic of Korea) 
according to the manufacturer’s instruction. 
One microgram of RNA was reverse-
transcribed using MMLV reverse 
transcriptase (Bioneer, Daejeon, Republic of 
Korea). Then, cDNA was amplified by PCR 
using specific primer iNOS (forward 5’-cct cct 
cca ccc tac caa gt-3’ and reverse 5’-cac cca 
aag tgcttc agt ca-3’), COX- 2 (forward 5’-aag 
act tgc cag gct gaa ct-3’ and reverse 5’-ctt ctg 
cag tcc agg ttc aa-3’) and β-actin (forward 5’-
tgt gat ggt ggg aat ggg tca g-3’ and reverse 
5’-ttt gat gtc acg cac gat ttc c-3’). The 
following PCR conditions were applied: COX-
2 and iNOS, 25 cycles of denaturation at 94 
ºC for 30 s, annealing at 59 ºC for 30 s and 
extended at 72 ºC for 30 s; β-actin, 23 cycles 
of denaturation at 94ºC for 30 s, annealing at 
57 ºC for 30 s and extended at 72 ºC for 30 s. 
β-actin was used as an internal control to 
evaluate relative expression of COX-2 and 
iNOS. 
 
Western blot analysis 
 
Total cell extracts were prepared using PRO-
PREP protein extraction solution (iNtRON 
Biotechnology). The preparation of cytosolic 
and nuclear extracts was conducted using 
NE-PER nuclear and cytosolic extraction 
reagents (Pierce, Rockford, IL, USA). Cell 
extracts were separated on polyacrylamide 
gels and then standard procedures were 
used to transfer them to the nitrocellulose 
membranes. The membranes were 
developed using an ECL reagent 
(Amersham, Arlington Heights, IL, USA). 
 
Electrophoretic mobility shift assay 
(EMSA) 
 
DNA-protein binding assays were carried out 
with nuclear extract. Synthetic complement-
tary NF-κB binding oligonucleotides (5’-AGT 
TGA GGG GAC TTT CCC AGG C-3’) were 
3’-biotinylated using the biotin 3’-end DNA 
labeling kit (Pierce, Rockford, IL, USA) 
according to the manufacturer’s instructions. 
Assays were performed using a Lightshift 
EMSA Optimization kit (Pierce) according to 




All data were derived from at least three 
independent experiments. Statistical 
analyses were conducted using SigmaPlot 
software (version 11.0) Values were 
presented as mean ± SE. Significant 
differences between the groups were 
determined using one-way ANOVA, with 
statistical significance set at p < 0.05. 
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RESULTS 
 
MEMC is not cytotoxic to BV2 microglial 
cells 
 
To evaluate the effects of MEMC on the 
viability of BV2 microglial cells, we incubated 
the cells with various concentrations of 
MEMC (0, 2.5, 5.0, 7.5 and 10.0 μg/ml) for 24 
h with or without incubation with LPS. Cell 
viability was assessed by the MTT assay and 
showed that MEMC did not exert significant 
cytotoxicity at all concentrations tested (Fig 
1). Solvent control (0.1 % DMSO) or LPS 
alone did not exert significant cytotoxicity, but 
a high concentration of MEMC of 20.0 μg/ml 
substantially induced cell death (data not 
shown). Therefore, concentrations of MEMC 
ranging from 0.0 to 10.0 μg/ml were selected 
for further studies. 
 
Fig 1: Effect of MEMC on BV2 microglial cell 
viability. Cells (1 × 105 cells/ml) were incubated 
with the indicated concentrations of MEMC 1 h 
before LPS (1.0 μg/ml) treatment for 24 h. Data 
are presented as mean ± SE, n = 3; *p < 0.05. 
 
MEMC suppresses NO and PGE2 
production 
 
To confirm the anti-inflammatory effects of 
MEMC in LPS-stimulated BV2 microglial 
cells, we investigated the production of NO 
using the Griess reagent assay. Fig 2A 
shows that LPS significantly increases NO 
production to 14.1 ± 1.2 μM; however, 
pretreatment with MEMC decreased LPS-
induced NO production to 10.4 ± 0.8 μM, 7.8 
± 0.7 μM, 6.2 ± 0.8 μM and 4.1 ± 0.3 μM in a 
dose-dependent manner. In particular, the 
highest concentration of MEMC reduced the 
NO levels comparable to that of the control 
group (3.2 ± 0.3 μM). In parallel, ELISA was 
performed to assess the effect of MEMC on 
LPS-stimulated secretion of PGE2 in BV2 
microglial cells. Similar to NO, MEMC 
significantly attenuated LPS-mediated PGE2 
production in a dose-dependent manner (Fig 
2B). Following LPS stimulation, PGE2 levels 
reached 1324 ± 35 pg/ml. However, a high 
concentration of MEMC (10 μg/ml) 
completely reduced the PGE2 levels to 421 ± 
12 pg/ml, comparable to the levels of the 
control group (311 ± 21 pg/ml). These data 
suggest that MEMC suppresses pro-
inflammatory mediators such as NO and 
PGE2 in LPS-stimulated BV2 microglial cells. 
 
 
Fig 2: Effect of MEMC on LPS-induced NO (A) 
and PGE2 (B) production in BV2 microglial cells; 
Cells (1 × 105 cells/ml) were treated with the 
indicated concentrations of MEMC 1 h before LPS 
(1.0 μg/ml) treatment for 24 h. (A) The levels of 
NO were determined using Griess reagent and a 
standard curve was constructed using NaNO2 in 
culture medium. (B) The levels of PGE2 in the 
media were detected using a specific enzyme-
linked immunosorbent assay. Data are presented 
as mean ± SE, n = 3; *p < 0.05. 
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MEMC attenuates iNOS and COX-2 
expression 
 
To investigate the expressional mechanism 
of pro-inflammatory mediators such as NO 
and PGE2 in LPS-induced BV2 microglial 
cells, we measured the expression of their 
respective regulatory genes, iNOS and COX-
2, both the protein and mRNA level using 
western blot analysis and RT-PCR. LPS 
treatment increased the expression of iNOS 
and COX-2 (Fig 3A) as well as their mRNA 
(Fig 3B). However, MEMC treatment 
significantly inhibited LPS-induced iNOS and 
COX-2 expression at both the mRNA and 
protein level. MEMC alone had no effect on 
the expression of these proteins and genes. 
These data indicate that MEMC regulates the 







Fig 3: Effect of MEMC on LPS-induced iNOS and 
COX-2 protein (A) and mRNA (B) expression in 
BV2 microglial cells. Cells (1 × 105 cells/ml) were 
incubated with MEMC (10 μg/ml) 1 h before LPS 
(1.0 μg/ml) treatment for 6 h. (A) Cell lysates were 
resolved on SDS-polyacrylamide gels, transferred 
to nitrocellulose membranes, and probed with 
antibodies against iNOS or COX-2. (B) Total RNA 
was isolated and RT-PCR analyses of iNOS and 
COX-2 were performed. Note: β-Actin was used 
as an internal control for the RT-PCR and Western 
blot analysis. 
MEMC modulates LPS-stimulated NF-κB 
activity 
 
NF-κB activation is essential to transactivate 
LPS-induced iNOS and COX-2 gene 
expression [10]. We measured the DNA-
binding activity of NF-κB and the nuclear 
translocation of NF-κB subunits p65 and p50 
as well as IκB degradation and 
phosphorylation. Treatment with LPS 
significantly increased DNA-binding activity of 
NF-κB as measured by the EMSA (Fig 4A). 
However, pretreatment with MEMC 
completely reduced LPS-induced DNA-
binding activity of NF-κB. In a parallel 
experiment, we found that LPS reduces the 
expression of p65 and p50 in the cytosolic 
fraction, and this correlated with an increase 
in phosphorylated IκB as measured by 
western blot analysis (Fig 4B). However, prior 
treatment with MEMC maintained stable p65 
and p50 levels in the cytosolic fractions and 
decreased the amount of phosphorylated IκB. 
In addition, we found that LPS treatment 
induced the nuclear translocation of p65 and 
p50; however, pretreatment with MEMC 
resulted in a decrease of these NF-κB 
subunits in the nuclear fraction (Fig 4C). 
These data indicate that MEMC inhibits NF-
κB activity by suppressing IκB-mediated 
nuclear translocation of NF-κB. 
 
MEMC inhibits LPS-stimulated NF-κB 
activity through suppression of Akt 
phosphorylation 
 
The Akt signaling pathway has been shown 
to regulate pro-inflammatory genes such as 
iNOS and COX-2 through activation of NF-κB 
[11]. Therefore, we examined the effect of 
MEMC on Akt phosphorylation in LPS-
stimulated BV2 microglial cells using western 
blot analysis. Phosphorylated Akt was 
significantly increased in LPS-stimulated BV2 
microglia cells; however, MEMC treatment 
produced an inhibition of Akt phosphorylation 
(Fig 5A).  
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Fig 4: Effect of MEMC on NF-κB activity in LPS-stimulated BV2 microglial cells. Cells were pretreated with 
MEMC (10 μg/ml) 1 h before stimulation with LPS (1.0 μg/ml) for 30 min. (A) The nuclear extracts were 
assayed for NF-κB activity by EMSA. The cytosolic (B) and nuclear (C) extracts were prepared to 
determine the levels of p65, p50, phosphor-IκBα and IκBα by western blot analysis. Note: β-Actin and c23 




Fig 5: Effect of MEMC on Akt phosphorylation in 
LPS-stimulated BV2 microglial cells. (A) Cells 
were pretreated with MEMC (10 μg/ml) 1 h before 
stimulation with LPS (1.0 μg/ml) for 30 min. 
Western blot analysis was performed to determine 
Akt phosphorylation. (B) Cells were treated with 
LY294002 (20 μM) 1 h before LPS (1.0 μg/ml) 
treatment for 30 min. EMSA measured NF-κB 
binding to its DNA promoter region in the nuclear 
protein extract. N.S. = non-specific. 
 
To verify that Akt activity is directly involved 
in NF-κB activation, we investigated the effect 
of the Akt inhibitor LY294002 on LPS-
stimulated NF-κB DNA-binding activity. We 
found that treatment with LY294002 
substantially reduced NF-κB-DNA binding in 
nuclear extracts (Fig 5B). These data indicate 
that MEMC inhibits LPS-induced NF-κB 




Several studies have reported that MEMC 
possesses anti-allergic and anti-cancer 
activities [12,13]. Nevertheless, there have 
been no reports on the effect of MEMC in 
LPS-stimulated inflammatory response. 
Therefore, we studied the anti-inflammatory 
properties of MEMC in LPS-stimulated BV2 
microglial cells. We first found that MEMC 
attenuates NO and PGE2 production and the 
expression of their respective regulatory 
genes, iNOS and COX-2, at both the mRNA 
and protein levels. In addition, we presented 
data that suggest that MEMC inhibits iNOS 
and COX-2 expression by suppressing NF-κB 
activity through the inhibition of Akt 
phosphorylation. 
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Microglias are glial cells that function in the 
central nervous system’s immune response 
against bacterial infection [14]. Microglias 
represent 20% of the total glial cell population 
in the mature brain [15]. When stimulated 
with LPS, microglias release NO and PGE2, 
which mediate traumatic brain injury following 
cerebral stroke [16]. Moreover, there is 
extensive evidence indicating that neural 
damage is absent in iNOS-deficient mice [17] 
and that inhibition of COX-2 expression after 
stroke in vivo exerts neuroprotective effects 
[18]. Therefore, the inhibition of pro-
inflammatory mediators such as NO and 
PGE2 is a potential therapeutic approach 
against neurodegenerative diseases. Our 
data demonstrated that MEMC significantly 
attenuates the expression of iNOS and COX-
2 as well as their respective gene products in 
LPS-stimulated BV2 microglial cells. We 
hypothesize that MEMC exerts neuro-
protective effects by inhibiting LPS-induced 
inflammatory responses. 
 
NF-κB is known to play an important role in 
the regulation of pro-inflammatory genes 
such as iNOS and COX-2 [4]. Therefore, 
targeting the NF-κB pathway represents a 
potential strategy to treat and prevent 
inflammatory diseases such as asthma and 
nervous disorders [19]. In the present study, 
we found that MEMC inhibits NF-κB activity 
by suppressing nuclear translocation of NF-
κB subunits p65 and p50 via the inhibition of 
IκB phosphorylation and degradation. To 
further explore NF-κB regulation, we 
investigated the relationship between Akt 
dephosphorylation and regulation of NF-κB 
activity, as it has been reported that many 
anti-inflammatory mediators are modulated 
by the Akt-dependent NF-κB signaling 
pathway [11]. In this study, MEMC 
significantly inhibited Akt phosphorylation, 
which suppresses NF-κB activation. These 
data demonstrate the potential of MEMC as a 
pharmaceutical agent for LPS-induced 
inflammatory disease. Nevertheless, recent 
studies showed that mitogen-activated 
protein kinases (MAPKs) and reactive oxygen 
species (ROS) are effector molecules that 
regulate NF-κB-dependent inflammatory 
reactions [20,21], although the role of ROS in 
NF-κB regulation remains controversial [22]. 
In addition, the transcription factor, AP-1, is 
also involved in the regulation of 
inflammation-associated gene expression in 
LPS-stimulated alveolar macrophages [23]. 
Therefore, further studies are required to 
elucidate the role of AP-1 and MAPKs in 




Our data demonstrate that MEMC inhibits 
anti-inflammatory mediators such as NO and 
PGE2, and their respective regulatory genes 
iNOS and COX-2 in LPS-stimulated BV2 
microglial cells. This anti-inflammatory effect 
results from the inhibition of Akt 
phosphorylation and the subsequent attenua-
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